Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
December 21, 2022 08:00 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it has achieved the target enrollment of approximately 3,000 participants in the groundbreaking...
Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal
December 14, 2022 08:30 ET
|
Dyadic International, Inc.
“Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge” Study supports: Dyadic’s...
The Wellness Coalition is Hosting Free Flu and COVID-19 Vaccine Clinics in December for a Safer Holiday Season
December 01, 2022 13:00 ET
|
The Wellness Coalition
MONTGOMERY, Ala., Dec. 01, 2022 (GLOBE NEWSWIRE) -- The Wellness Coalition is hosting community COVID-19 and flu vaccine clinics in Montgomery, Tuskegee, and Pike Road during the month of December....
As Flu Cases Climb Early, Hospitals Gearing Up With US Med-Equip
October 20, 2022 07:00 ET
|
US Med-Equip
HOUSTON, Oct. 20, 2022 (GLOBE NEWSWIRE) -- With the CDC reporting flu cases starting to climb, healthcare providers across the U.S. are preparing for an early wave of influenza this winter. In...
Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A
October 18, 2022 08:00 ET
|
Vir Biotechnology, Inc.
– First clinical trial evaluating the role of a monoclonal antibody in preventing seasonal flu – – Announcement follows recent U.S. government award from the Biomedical Advanced Research and...
Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential
October 04, 2022 08:45 ET
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
October 04, 2022 08:00 ET
|
Vir Biotechnology, Inc.
– First award from the agency’s solicitation for contracts for Pre-Exposure Prophylaxis for Influenza – – Initial investment of approximately $55 million from Biomedical Advanced Research and...
SRW Introduces Imm1 Defence for Immunity Protection and Energy Support During Recovery
July 12, 2022 17:50 ET
|
SRW
AUCKLAND, New Zealand, July 12, 2022 (GLOBE NEWSWIRE) -- Egg yolks have long been known to have immune health benefits primarily because of their high levels of natural IgY (immunoglobulin yolk)...
Dyadic Announces Successful Toxicology Data Published in “Toxicologic Pathology”
May 09, 2022 08:30 ET
|
Dyadic International, Inc.
Toxicology data published in the international peer-reviewed scientific journal “Toxicologic Pathology” demonstrates excellent safety profile and lasting immunogenic response from Dyadic’s DYAI-100,...
Kroger Health and Gravity Diagnostics Partner to Offer 3-in-1 Multiplex Testing at all Kroger Little Clinics
January 20, 2022 13:17 ET
|
Gravity Diagnostics
Covington, Kentucky, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Gravity Diagnostics’ 3-in-1 multiplex tests for flu A/B, RSV, and COVID-19 combined, to help differentiate these three types of infections in...